Samsung Biologics storms into obesity drug market with $1.8 billion proposed takeover of PolyPeptide Group
SEOUL: Samsung Biologics announced on Monday an all-cash bid of 1.46 billion Swiss francs ($1.8 billion) to acquire Switzerland’s PolyPeptide Group, a specialist in peptide-based active pharmaceutical ingredients. The deal marks the largest biopharmaceutical merger and acquisition in South Korean history,…